Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 4/20 | 1.00 |
| ▸ | ACHE | P22303 | 5/20 | 0.76 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.65 |
| ▸ | HTR1A | P08908 | 3/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | HTR2B | P41595 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30423421 | 0.85 | METAP1 (0.74) | METAP1ACHESIGMAR1HTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL29583950 | 0.84 | METAP1 (0.74) | METAP1ACHESIGMAR1HTR1ADRD2 | |
| SCHEMBL5356984 | 0.84 | METAP1 (0.72) | METAP1ACHESIGMAR1HTR1ADRD2 | |
| SCHEMBL11729469 | 0.78 | METAP1 (0.64) | METAP1ACHESIGMAR1HTR1A | |
| SCHEMBL1274057 | 0.78 | METAP1 (0.63) | METAP1ACHESIGMAR1HTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL11637948 | 0.76 | HTR2C (0.78) | METAP1ACHEDRD2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL11246855 | 0.76 | METAP1 (0.62) | METAP1ACHE | |
| SCHEMBL11734231 | 0.75 | METAP1 (0.58) | METAP1ACHESIGMAR1HTR1ADRD2 | |
| SCHEMBL9228040 | 0.74 | SIGMAR1 (0.62) | METAP1ACHESIGMAR1HTR1A | |
| SCHEMBL7662896 | 0.74 | METAP1 (0.57) | METAP1ACHESIGMAR1HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129549-A1 | Stable lamotrigine pharmaceutical compositions and processes for their preparation | RANBAXY LABORATORIES LIMITED (IN) | 2007-06-07 | — | — | US | disclosed |
| US-20070129549-A1 | Stable lamotrigine pharmaceutical compositions and processes for their preparation | RANBAXY LABORATORIES LIMITED (IN) | 2007-06-07 | — | — | US | disclosed |
| EP-1608371-A1 | PROCESS FOR THE PREPARATION OF DONEPEZIL AND DERIVATIVES THEREOF | RANBAXY LABORATORIES, LTD. (IN) | 2005-12-28 | — | — | EP | disclosed |
| EP-1608371-A1 | PROCESS FOR THE PREPARATION OF DONEPEZIL AND DERIVATIVES THEREOF | RANBAXY LABORATORIES, LTD. (IN) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004082685-A1 | PROCESS FOR THE PREPARATION OF DONEPEZIL AND DERIVATIVES THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2004-09-30 | — | — | WO | disclosed |
| WO-2004082685-A1 | PROCESS FOR THE PREPARATION OF DONEPEZIL AND DERIVATIVES THEREOF | RANBAXY LABORATORIES LIMITED (IN) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129549-A1 | Stable lamotrigine pharmaceutical compositions and processes for their preparation | KCNJ1, KCNJ8, KCNJ2 | METAP1 2326/4885ACHE 126/4885SIGMAR1 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.